Congresses and Publications

Combination treatment with novel BCL2 inhibitor sonrotoclax (BGB-11417) and zanubrutinib induces high rate of complete remission in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) Combination treatment with sonrotoclax (BGB-11417) + zanubrutinib is well tolerated and achieves deep responses in patients with treatment-naive (TN) CLL/SLL: data from an ongoing phase 1/2 study Monotherapy with second-generation BCL2 inhibitor sonrotoclax (BGB-11417) is well tolerated with high response rates in relapsed/refractory (R/R) marginal zone lymphoma (MZL): data from an ongoing phase 1 study Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory (R/R) CLL/SLL: results from the phase 1 BGB-16673-101 study Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax (BGB-11417) in combination with zanubrutinib for relapsed/refractory (R/R) CLL/SLL show deep and durable responses Sonrotoclax plus dexamethasone was tolerable and demonstrated antimyeloma activity in patients with relapsed/refractory (R/R) multiple myeloma (MM) harboring t(11;14)

Zanubrutinib for the treatment of primary membranous nephropathy (PMN): Results of a single-arm feasibility study

Safety and pharmacokinetic profile from a phase 1 trial of BGB dinutuximab beta-101 as maintenance therapy in pediatric patients with high-risk neuroblastoma in China

BGB-11417-203, an ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory Waldenström macroglobulinemia: Results from the phase 1 CaDAnCe-101 study Safety and efficacy results of a phase 1 study of the novel BCL2 inhibitor sonrotoclax (BGB-11417) for relapsed/refractory Waldenström macroglobulinemia Zanubrutinib is well tolerated and effective in ibrutinib/acalabrutinib-intolerant patients with Waldenström macroglobulinemia

Improving the quality of active monitoring in Waldenström macroglobulinemia: Results of a UK-wide patient-centered experience survey and proposed standard of care for active monitoring from a UK-wide patient-expert collaboration Peripheral neuropathy in phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia

BGB-11417-203, an ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia Improving the quality of active monitoring in Waldenström macroglobulinemia: Results of a UK-wide patient-centered experience survey and proposed standard of care for active monitoring from a UK-wide patient-expert collaboration Peripheral neuropathy in phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory Waldenström macroglobulinemia: Results from the phase 1 CaDAnCe-101 study Safety and efficacy results of a phase 1 study of the novel BCL2 inhibitor sonrotoclax (BGB-11417) for relapsed/refractory Waldenström macroglobulinemia

Combination of zanubrutinib (zanu) + venetoclax (ven) for treatment-naive (TN) CLL/SLL with del(17p) and/or TP53: preliminary results from SEQUOIA arm D Combination treatment (tx) with novel BCL2 inhibitor sonrotoclax (sonro; BGB-11417) and zanubrutinib (zanu) induces high rate of complete remission in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) indolent NHL: results from the phase 1 BGB-16673-101 study Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 Inhibitor, in treatment-naive (TN) patients with acute myeloid leukemia (AML) Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in patients (pts) with relapsed/refractory (R/R) acute myeloid leukemia (AML) Sonrotoclax (sonro; BGB-11417) + dexamethasone (dex) is tolerable and demonstrates antimyeloma activity in patients with relapsed/refractory (R/R) multiple myeloma (MM) harboring t(11;14)

2 years of zanubrutinib in Germany: a retrospective cohort study Outcomes ≥1 year after transitioning from treatment with ibrutinib (ibru) in the ASPEN study to zanubrutinib (zanu) Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) CLL/SLL: results from the phase 1 BGB-16673-101 study Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax (sonro; BGB-11417) in combination with zanubrutinib (zanu) for relapsed/refractory (R/R) CLL/SLL show deep and durable responses Safety and efficacy results of a phase 1 study of the novel BCL2 inhibitor sonrotoclax (sonro; BGB-11417) for relapsed/refractory (R/R) Waldenström macroglobulinemia (WM)

2 years of zanubrutinib in Germany: a retrospective cohort study Combination of zanubrutinib (zanu) + venetoclax (ven) for treatment-naive (TN) CLL/SLL with del(17p) and/or TP53: preliminary results from SEQUOIA arm D Combination treatment (tx) with novel BCL2 inhibitor sonrotoclax (sonro; BGB-11417) and zanubrutinib (zanu) induces high rate of complete remission in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): minimum 3-year survival follow-up Outcomes ≥1 year after transitioning from treatment with ibrutinib (ibru) in the ASPEN study to zanubrutinib (zanu) Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) CLL/SLL: results from the phase 1 BGB-16673-101 study Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) indolent NHL: results from the phase 1 BGB-16673-101 study Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 Inhibitor, in treatment-naive (TN) patients with acute myeloid leukemia (AML) Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in patients (pts) with relapsed/refractory (R/R) acute myeloid leukemia (AML) Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax (sonro; BGB-11417) in combination with zanubrutinib (zanu) for relapsed/refractory (R/R) CLL/SLL show deep and durable responses Safety and efficacy results of a phase 1 study of the novel BCL2 inhibitor sonrotoclax (sonro; BGB-11417) for relapsed/refractory (R/R) Waldenström macroglobulinemia (WM) Sonrotoclax (sonro; BGB-11417) + dexamethasone (dex) is tolerable and demonstrates antimyeloma activity in patients with relapsed/refractory (R/R) multiple myeloma (MM) harboring t(11;14)

Combination treatment with sonrotoclax (BGB-11417), a second-generation BCL2 inhibitor, and zanubrutinib, a Bruton tyrosine kinase (BTK) inhibitor, is well tolerated and achieves deep responses in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN-CLL/SLL): data from an ongoing phase 1/2 study Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory (R/R) CLL/SLL: Results from the phase 1 BGB-16673-101 study Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax in combination with zanubrutinib for relapsed/refractory (R/R) CLL/SLL show deep and durable response

Combination treatment with sonrotoclax (BGB-11417), a second-generation BCL2 inhibitor, and zanubrutinib, a Bruton tyrosine kinase (BTK) inhibitor, is well tolerated and achieves deep responses in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN-CLL/SLL): data from an ongoing phase 1/2 study Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory (R/R) CLL/SLL: Results from the phase 1 BGB-16673-101 study Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax in combination with zanubrutinib for relapsed/refractory (R/R) CLL/SLL show deep and durable response